Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Hong Chen

Physician Assistant Brooklyn, NY Physician Assistant

NPI 1689921934 CMS profile 11000266

356 Bay Ridge Ave Fl 1, Brooklyn, NY 11220

Open in the dashboard

General payments

$56,511

871 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hong Chen of Brooklyn, NY is reported in the CMS Open Payments database as having received $56,511 across 871 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,509 111
2024 General $18,822 188
2023 General $7,042 168
2022 General $10,585 230
2021 General $10,553 174

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hong Chen
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Hong Chen were reported at $9,509. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Hong Chen Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $10,553 $132 $37–$438 $132
2022 $10,585 $155 $48–$522 $149
2023 $7,042 $167 $52–$557 $160
2024 $18,822 $178 $55–$600 $164
2025 $9,509 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Gilead Sciences, Inc. $22,331 152 payments
  2. Phathom Pharmaceuticals, Inc. $10,826 38 payments
  3. IBSA Pharma Inc. $4,701 38 payments
  4. AbbVie, Inc. $2,851 95 payments
  5. Esperion Therapeutics, Inc. $2,321 68 payments
  6. Biohaven Pharmaceuticals, Inc. $2,084 21 payments
  7. Amgen Inc. $1,948 57 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $1,503 54 payments
  9. AstraZeneca Pharmaceuticals LP $1,258 43 payments
  10. Novo Nordisk Inc $1,002 32 payments
  11. Other $5,685 273 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,740 24 payments
  2. Food and Beverage $23,516 812 payments
  3. Travel and Lodging $5,704 26 payments
  4. Consulting Fee $3,525 7 payments
  5. Education $25 2 payments
Products named General payments · program years 2021–2025
  1. VOQUEZNA $10,704 30 payments
  2. Vemlidy $10,269 26 payments
  3. Licart $4,301 37 payments
  4. NURTEC ODT $2,888 48 payments
  5. NEXLETOL $2,321 68 payments
  6. Otezla $1,300 44 payments
  7. UBRELVY $1,250 48 payments
  8. Flector $1,036 16 payments
  9. NEXLIZET $1,020 7 payments
  10. Repatha $938 34 payments
  11. Other $12,998 596 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 177 drugs

Part D claims

15,500

Median for Physician Assistant: 241

Drug cost

$4,283,264

Median for Physician Assistant: $4,110

Branded share of claims

31.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Epolamine Generic 1,019 $937,575
Diclofenac Potassium Generic 225 $451,574
Vascepa Icosapent Ethyl Brand 819 $404,962
Vemlidy Tenofovir Alafenamide Brand 173 $254,304
Januvia Sitagliptin Phosphate Brand 163 $148,884
Rybelsus Semaglutide Brand 109 $148,489
Farxiga Dapagliflozin Propanediol Brand 161 $146,003
Zenpep Lipase/Protease/Amylase Brand 57 $137,072
Restasis Cyclosporine Brand 117 $116,861
Otezla Apremilast Brand 18 $88,999

The 10 drugs with the highest cost, of 177 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
$6,377 24 —
Vemlidy
$3,965 173 —
Licart
$2,587 42 —
Repatha
$252 14 —
AIRSUPRA
$250 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

871 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record